Skip to main navigation Skip to search Skip to main content

Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial

  • Lucia Musacchio
  • , Margherita Turinetto
  • , Laura Arenare
  • , Michele Bartoletti
  • , Daniela Califano
  • , Valentina Tuninetti
  • , Claudia Marchetti
  • , Gennaro Cormio
  • , Vera Loizzi
  • , Carmela Pisano
  • , Vanda Salutari
  • , Giorgio Valabrega
  • , Domenico Priolo
  • , Sabrina Chiara Cecere
  • , Jole Ventriglia
  • , Francesco Raspagliesi
  • , Francesco Perrone
  • , Anna Fagotti
  • , Domenica Lorusso
  • , Giovanni Scambia
  • Sandro Pignata
  • University of Turin
  • IRCCS Istituto nazionale tumori Fondazione Giovanni Pascale - Napoli
  • IRCCS Centro di Riferimento Oncologico - Aviano PN
  • IRCCS Istituto tumori Giovanni Paolo II - Bari
  • San Vincenzo Hospital
  • IRCCS Fondazione Istituto Nazionale per lo studio e la cura dei tumori - Milano

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)72-77
Number of pages6
JournalGynecologic Oncology
Volume172
DOIs
Publication statusPublished - 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • MITO 22 trial
  • bevacizumab
  • varian cancer

Cite this